Henderson Michael Thomas
- SEC CIK
- 0001779990
In the past year, 13 open-market sale filings worth $36.3M and no purchases.
Current role at each company
- CIK 0001974640Chief Executive Officeras of Sep 3, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of Jun 23, 2026
- CIK 0001838821Directoras of Jul 31, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $36.3M
- 13 filings
- Net
- −$36.3M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Henderson Michael Thomas as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CIK 0001974640
Chief Executive Officer20 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)8:00 PM ET | Jul 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $133.63 | −$2.67M | −2.0%996.0K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −80.0K | $132.54 | −$10.6M | −7.3%1.02M after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $83.38 | −$1.67M | −1.8%1.10M after | 6 lots10b5-1 |
| May 15, 2026 (view filing) | May 13 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.09 | −$1.64M | −1.8%1.12M after | 2 lots10b5-1 |
| Apr 10, 2026 (view filing) | Apr 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.58 | −$1.65M | −1.7%1.13M after | 3 lots10b5-1 |
| Mar 13, 2026 (view filing) | Mar 11 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $74.78 | −$1.50M | −1.7%1.15M after | 3 lots10b5-1 |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $63.35 | −$1.27M | −1.7%1.17M after | 3 lots10b5-1 |
| Jan 16, 2026 (view filing) | Jan 14 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $81.11 | −$1.62M | −1.6%1.19M after | 6 lots10b5-1 |
| Dec 12, 2025 (view filing) | Dec 10 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $75.38 | −$1.51M | −1.6%1.21M after | 3 lots10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $75.01 | −$3.00M | −3.1%1.23M after | 10b5-1 |
SYRE Spyre Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Henderson Michael ThomasDirector | SSale | −20.0K | $100.00 | −$2.00M | −22.6%68.6K after | 10b5-1 |
| May 8, 2026 (view filing) | May 8 | Same day | Henderson Michael ThomasDirector | SSale | −80.0K | $74.40 | −$5.95M | −47.4%88.6K after | 4 lots10b5-1 |